Progress of research on molecular targeted therapies for colorectal cancer
S Huang, J Ye, X Gao, X Huang, J Huang… - Frontiers in …, 2023 - frontiersin.org
Colorectal cancer (CRC) is one of the most common malignancies, accounting for
approximately 10% of global cancer incidence and mortality. Approximately 20% of patients …
approximately 10% of global cancer incidence and mortality. Approximately 20% of patients …
The role of anti-EGFR monoclonal antibody in mCRC maintenance therapy
M Yuan, Z Wang, W Lv, H Pan - Frontiers in Molecular Biosciences, 2022 - frontiersin.org
Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs)
combined with chemotherapy in patients with RAS (rat sarcoma viral oncogene homolog) …
combined with chemotherapy in patients with RAS (rat sarcoma viral oncogene homolog) …
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer …
DP Modest, M Karthaus, S Fruehauf… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE The randomized PANAMA trial investigated the efficacy of panitumumab (Pmab)
when added to maintenance therapy with fluorouracil and folinic acid (FU/FA) in patients …
when added to maintenance therapy with fluorouracil and folinic acid (FU/FA) in patients …
Maintenance therapy with cetuximab after FOLFIRI plus cetuximab for RAS wild-type metastatic colorectal cancer: A phase 2 randomized clinical trial
V Boige, H Blons, E François, MB Abdelghani… - JAMA Network …, 2023 - jamanetwork.com
Importance The optimal maintenance strategy after induction chemotherapy with anti–
epidermal growth factor receptor antibody for patients withRASwild-type metastatic …
epidermal growth factor receptor antibody for patients withRASwild-type metastatic …
[HTML][HTML] Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: a systematic review and Bayesian network meta-analysis
L Mastrantoni, V Beccia, G Caira, G Trovato… - Critical Reviews in …, 2023 - Elsevier
Background In RAS wild type (wt) metastatic colorectal cancer (mCRC) maintenance
therapy after induction with fluoropyrimidine (FP)-based cytotoxic therapy (CT) plus anti …
therapy after induction with fluoropyrimidine (FP)-based cytotoxic therapy (CT) plus anti …
[HTML][HTML] Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: an individual …
A Raimondi, F Nichetti, A Stahler, HS Wasan… - European Journal of …, 2023 - Elsevier
Background Anti-EGFR antibodies plus doublet chemotherapy is the standard of care in
RAS/BRAF wild-type metastatic colorectal cancer (mCRC). No phase-3 level of evidence is …
RAS/BRAF wild-type metastatic colorectal cancer (mCRC). No phase-3 level of evidence is …
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic …
A Stahler, B Hoppe, IK Na, L Keilholz… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Consensus molecular subtypes (CMSs) were evaluated as prognostic and
predictive biomarkers of patients with RAS wild-type metastatic colorectal cancer (mCRC) …
predictive biomarkers of patients with RAS wild-type metastatic colorectal cancer (mCRC) …
[HTML][HTML] Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre …
A Raimondi, G Fucà, AG Leone, S Lonardi, C Antoniotti… - ESMO open, 2021 - Elsevier
Background The safety and efficacy outcome of elderly metastatic colorectal cancer (mCRC)
patients fit enough to receive combination chemotherapy plus biological agents is an issue …
patients fit enough to receive combination chemotherapy plus biological agents is an issue …
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic …
C Pinto, A Orlandi, N Normanno, E Maiello… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE The intensity of anti-EGFR–based first-line therapy for RAS/BRAF wild-type (wt)
metastatic colorectal cancer (mCRC), once disease control is achieved, is controversial. A …
metastatic colorectal cancer (mCRC), once disease control is achieved, is controversial. A …
The validity of surrogate endpoints in sub groups of metastatic colorectal cancer patients defined by treatment class and KRAS status
H Poad, S Khan, L Wheaton, A Thomas, M Sweeting… - Cancers, 2022 - mdpi.com
Simple Summary When evaluating new cancer therapies in clinical trials, it may take a long
time to estimate their effectiveness on overall survival, an outcome typically of main interest …
time to estimate their effectiveness on overall survival, an outcome typically of main interest …